HeartFlow Beats Q2 EPS by 6 Cents, Raises Guidance; Stock Surges 36% to 52-Week High
HTFL has more than doubled off its 52-week low of $20.13 on elevated volume (6.2× avg).
Summary
HeartFlow delivered a strong Q2: adjusted loss of $0.07 per share beat the $0.13 loss estimate, revenue jumped 48% to $64.1M, and gross margin hit 83%. The company raised full-year revenue guidance to $246-$250M from $228-$232M. Shares are up 36% to a new 52-week high. This follows the 8-K filed yesterday that first disclosed the revenue and guidance raise; today's report adds the EPS beat, margin details, and the market's reaction. The stock is now trading near resistance at $43, and the raised guidance suggests continued momentum in FFRCT and Plaque adoption.
At the time of this announcement, HTFL was trading at $41.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $20.13 to $43.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.